$ALMS
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
Healthcare
Sector
Biotechnology
Industry
Martin Babler
CEO
168
Employees
$25.06
Current Price
$2.87B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 months | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 3 months | Buys | 4 | 7 | $30,999,959.00 | 1,823,527 | All Buys |
| Sells | 0 | 0 | - | - | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Jan 9, 2026 | AKKARAJU SRINIVAS Director | Purchase | 588,235 | $17.00 | $9,999,995.00 | View Details |
| Jan 8, 2026 | Foresite Labs, LLC 10% Owner | Purchase | 294,117 | $17.00 | $4,999,989.00 | View Details |
| Jan 8, 2026 | Foresite Labs, LLC 10% Owner | Purchase | 117,647 | $17.00 | $1,999,999.00 | View Details |
| Jan 8, 2026 | Foresite Capital Management VI LLC 10% Owner | Purchase | 117,647 | $17.00 | $1,999,999.00 | View Details |
| Jan 8, 2026 | Foresite Capital Management VI LLC 10% Owner | Purchase | 294,117 | $17.00 | $4,999,989.00 | View Details |
| Jan 8, 2026 | Tananbaum James B. Director | Purchase | 294,117 | $17.00 | $4,999,989.00 | View Details |
| Jan 8, 2026 | Tananbaum James B. Director | Purchase | 117,647 | $17.00 | $1,999,999.00 | View Details |
41 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Past Earnings
Historical earnings results
EPS
Estimated-$0.92
Actual-$0.95
Miss
Revenue
Estimated$2.89M
Actual$1.93M
Miss
EPS
Estimated-$0.99
ActualN/A
Revenue
Estimated$2.40M
ActualN/A
3 more earnings records available โ create a free account to see 12 months of history
Related Activity
Cross-company insider connections and cluster buy signals
Cluster Buy Signals
$ALMS appeared in 2 cluster buy signals:
Insiders Also Active At
Insiders at this company also hold positions or have traded at these companies: